On Jan. 1, Dave Ricks becomes CEO of drugmaker Eli Lilly and Co. as it tries to launch new products after a tough stretch of patent expirations. To prepare, Ricks has spent a lot of time with outgoing CEO John Lechleiter “learning from the master.”
Research developed at Purdue University and licensed by a biomedical startup could give patients with late-stage prostate cancer an alternative to hormone therapies that can develop resistance after prolonged use.
This is shaping up to be the most difficult sign-up season since HealthCare.gov launched in 2013. Premiums are going up sharply in many parts of the country, and some major insurers have exited the program, leaving consumers with fewer choices.
Eli Lilly and Co. is pledging $90 million over five years to improve access to treatment for diabetes, cancer and tuberculosis in developing countries—the latest push in its philanthropic strategy of building health care systems around the world and increasing the market for its prescription drugs.
The residents who sued sought to revoke the school’s property-tax exemption, in part because Princeton shares commercial royalties with faculty from a patent that Indianapolis-based Eli Lilly and Co. turned into the cancer drug Alimta.